Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.
Ondine Biomedical Inc. has begun recruiting patients for a pilot study of its Steriwave nasal photodisinfection technology in the ICU at Royal Columbian Hospital in British Columbia. This study aims to evaluate the feasibility of a larger trial to assess Steriwave’s effectiveness in reducing hospital-acquired infections among critically ill patients, addressing a significant challenge in healthcare due to antimicrobial resistance. The study’s results could lead to a multicentre trial involving up to 2,000 patients, potentially positioning Steriwave as a key technology in ICU infection prevention. Additionally, Ondine will issue new shares as part of the clinical trial agreement, reflecting the company’s milestone achievement in enrolling the first patient.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, with applications in various medical fields, including chronic sinusitis, ventilator-associated pneumonia, and burns. Its nasal photodisinfection system, Steriwave, is approved in Canada and several other countries and is undergoing clinical trials in the US.
YTD Price Performance: 17.14%
Average Trading Volume: 272,005
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £41.41M
For detailed information about OBI stock, go to TipRanks’ Stock Analysis page.